CAL-101: Interim Phase I data

Interim data from 17 evaluable patients with relapsed or refractory chronic lymphocytic leukemia (CLL) in an expansion stage of an ongoing, open-label, U.S. Phase I trial showed that 200 or 350 mg ora...